Private equity firm GTCR has struck a 4.1 billion euro ($4.8 billion) deal to buy Czech generic drug maker Zentiva from Advent International, the Financial Times reported on Wednesday, citing unnamed sources.
Reuters could not immediately confirm the report. GTCR, Advent and Zentiva did not respond to Reuters’ request for comment. The newspaper said the deal has been completed and will be announced in the coming days.
Boston-based Advent acquired Zentiva, which produces a wide range of generics and over-the-counter drugs, from French pharmaceutical giant Sanofi for 1.9 billion euros in 2018.
According to the company’s website, Zentiva operates in more than 30 countries and has over 5,000 employees.
Last month, the Indian newspaper Economic Times reported that Aurobindo Pharma was leading the race to acquire Zentiva with an offer of up to $5.5 billion.
Source: Reuters